Novio Tech Campus
About Lead PharmaLead Pharma is a biopharmaceutical company focusing on the discovery and development of innovative medicines for the treatment of autoimmune diseases and cancer. Lead Pharma’s drug discovery engine combines medicinal, structural, and computational chemistry with molecular pharmacology, cell and tissue-based pharmacology. Thereby, the company aims to identify first and / or best-in-class small molecule drugs. Based in Nijmegen and Oss, the Netherlands, Lead Pharma is privately owned and is financed by Biox Biosciences, Participatiemaatschappij Oost Nederland N.V. (PPM Oost), Life Sciences & Health Fund B.V., and Technostartersfonds Zuid Nederland B.V. For more information visit: www.leadpharma.com
CEO: Ad van Gorp
CSO: Arthur Oubrie
Please click here for clinical trial information.
7 articles about Lead Pharma
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Lead Pharma has entered into a collaboration and license agreement with Roche, hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases.
Lead Pharma enters into a Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases
R&D collaboration building on Lead Pharma's expertise in the discovery, design and optimization of small molecule treatments
Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis
Sanofi, Lead Pharma’s collaborative partner in the development of SAR441169, successfully initiated first human dosing with this novel RORγt Inverse Agonist candidate treatment
Lead Pharma Achieves Third Milestone in Sanofi Collaboration for Development of Autoimmune Diseases Treatments
The collaboration aims to develop small molecules directed against the nuclear hormone receptor ROR gamma (t) for the treatment of a broad range of autoimmune disorders, including common diseases such as psoriasis, rheumatoid arthritis and inflammatory bowel disease.
Lead Pharma Achieves Second Milestone For Development Of Autoimmune Diseases Treatments In Sanofi Collaboration